Pyxis Oncology, Inc. (PYXS)
Health Care · Biotechnology · NASDAQ
A clinical-stage oncology company developing a novel antibody-drug conjugate targeting the tumor microenvironment to treat difficult-to-treat solid tumors like HNSCC.
What Pyxis Oncology, Inc. does
Pyxis Oncology is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for patients with difficult-to-treat solid tumors. The company's lead candidate, micvotabart pelidotin (MICVO), is an antibody-drug conjugate (ADC) designed to target EDB+FN, a splice variant of fibronectin highly expressed in the tumor microenvironment. Pyxis is evaluating MICVO both as a monotherapy and in combination with checkpoint inhibitors for various solid tumor indications, particularly head and neck squamous cell carcinoma (HNSCC).
Recent developments
The company completed a private placement financing in July 2026 for approximately $50 million in upfront gross proceeds, extending its cash runway into the second quarter of 2027. Updated Phase 1 clinical data for MICVO in 2L+ R/M HNSCC is expected in Fall 2026, with updated combination data with pembrolizumab in 1L R/M HNSCC expected in the fourth quarter of 2026.
From Pyxis Oncology, Inc.'s filing of 2026-08-13.
Themes: oncology, antibody-drug conjugates (ADCs), tumor microenvironment, clinical-stage biopharma, HNSCC therapy development
Fundamentals
- Price$1.84 as of 2026-10-20 close
- Market cap$153M as of 2026-08-12 (share count; price 2026-10-20)
- 1-year return-48.6% 2025-10-20 close $3.58 → 2026-10-20 close $1.84
- P/En/a negative earnings
- Net margin-574.5% FY2025, SEC XBRL
- ROE-149.1% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)-14.2% FY2025, SEC XBRL
- Beta1.37 as of 2026-09-02
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How PYXS compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-02
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-02
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | — | -$26M | -$25M | -$0.40 | -$18M† | — |
| Q1 FY2026 2026-03-31 | — | -$24M | -$23M | -$0.37 | -$26M | — |
| Q4 FY2025 2025-12-31 | $11M† | -$18M† | -$18M† | -$0.29† | -$10M† | $0† |
| Q3 FY2025 2025-09-30 | — | -$23M | -$22M | -$0.35 | -$13M† | — |
| Q2 FY2025 2025-06-30 | $3M | -$20M | -$18M | -$0.30 | -$17M† | — |
| Q1 FY2025 2025-03-31 | — | -$23M | -$21M | -$0.35 | -$23M | — |
| Q4 FY2024 2024-12-31 | — | -$40M† | -$36M† | -$0.59† | -$19M† | $0† |
| Q3 FY2024 2024-09-30 | — | -$24M | -$21M | -$0.35 | -$15M† | $0† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$19M
- Short-term investments$14M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Pyxis Oncology, Inc. looks technically
Pyxis Oncology, Inc. (PYXS) is trading 14.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 52 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 32, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago. It is 66.8% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 14.0% below its 200-day average, the long-term trend line — a long-term downtrend | -14.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.86 | $2.86 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.14 | $2.14 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 39 calendar days ago — the swings before that are what the structure reading is measured on | 39 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 52 trading days ago — a "golden cross", a bullish long-term signal | 52 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with sellers in control | 41.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 32, neither overbought (above 70) nor oversold (below 30) | 32.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($1.66 to $2.31) — its "stochastic" reading is 28 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 27.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 29 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $5.55 | $5.55 |
|---|---|---|
| From the 52-week high | it is 66.8% below its 52-week high (its highest price of the past year) | -66.8% |
| Above the 52-week low | it is 78.6% above its 52-week low (its lowest price of the past year) | +78.6% |
| Below the 52-week high | it is 66.8% below its highest point of the past year | 66.8% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $14.00 (set on 2021-11-03) | $14.00 |
| Given back of the 52-week move | over the past year its closes ranged ($1.06 to $5.34), and it has recovered roughly a quarter of its fall from last year’s high — 18% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.71 to $3.84. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 18.2% |
| From the all-time high | it is 86.9% below its all-time high | -86.9% |
| Nearest price level | it is trading 0.5% above a support level at $1.83 — a price it turned at twice since 2025-01-07, most recently on 2026-04-14. Since 2024-10-21 it has 9 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.5% |
| All-time low | its lowest closing price on record is $0.833 (set on 2025-04-07) | $0.833 |
| Above the all-time low | it is 120.9% above its all-time low | +120.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 91% of the past ~6 months) | 91st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1953 between its high and its low — about 10.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1953 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.31 and $3.14 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.31 – $2.22 – $3.14 |
| Typical daily range (% of price) | its price moves about 10.6% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 10.6% |
| Stretch from the 200-day average | it is trading 1.5 daily ranges below its 200-day average price (14.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.86× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a hammer | 8 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 8 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-20 1.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.6% |
|---|---|---|
| Open gap | it gapped 18.1% below the previous close 14 sessions ago and has not traded back through the level it left behind at 2.9 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -18.1% |
| Gap filled | a 2.7% gap up opened on 2026-09-17 has been "filled" 23 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 23 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +9.52% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 45.7 percentage points (the stock lost 44.7% while the market gained 1.0%) | -45.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 21.9 percentage points (the stock lost 18.2% while the market gained 3.6%) | -21.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 0.3 percentage points (the stock gained 8.2% while the market gained 8.5%) | -0.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 63.2 percentage points (the stock lost 48.6% while the market gained 14.6%) | -63.2% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 39% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 15.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -39.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 23% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.40 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | -23.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 33% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $2.74 — a volume-weighted average of daily closes over 48 sessions, not a true tick-by-tick VWAP. | -32.7% |
Price levels it has turned at before
PYXS last closed at $1.84 on 2026-10-20. Since 2024-10-21 it has turned at 9 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.83 | Support | 0.5% below the last close | turned there twice · 2025-01-07 to 2026-04-14 |
| $1.70 | Support | 7.9% below the last close | turned there twice · 2026-02-06 to 2026-03-18 |
| $1.50 | Support | 18.5% below the last close | turned there twice · 2024-12-19 to 2024-12-31 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · Most volatile (6%+ typical daily range) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.30 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$8.67 range $6.00 – $19.00; median $8.00
Analyst estimates, as of 2026-10-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PYXS
- Consensus EPS estimate-$0.2778 next reporting period, as of 2026-10-18
- Estimate change, 30 days$0.00 from -$0.2778, on 2026-09-13, 35-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical stage company with no commercial products and a history of net losses, which are expected to continue.","Reliance on the successful development and regulatory approval of a single lead product candidate (MICVO).","Potential safety and tolerability issues associated with ADC payload administration, particularly in certain patient populations."]
What changed in the latest 10-Q
AI-assisted comparison of PYXS's 10-Q filed 2026-05-14 against the prior one filed 2025-11-03.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references 'Fiscal 2025 10-K' (filed 2026-05-14) vs. older references 'Fiscal 2024 10-K' (filed 2025-11-03)
- Newer filing includes description of MICVO's three-pronged mechanism of action: (1) direct payload kill, (2) bystander effect, (3) immunogenic cell death (ICD) triggering via neoantigens
- Newer filing specifies payload as 'Aur0101' (optimized auristatin)
- Newer filing mentions MICVO being studied in combination with KEYTRUDA (pembrolizumab) in 1L/2L+ R/M HNSCC and other solid tumors
- Newer filing describes Phase 1 Part 2 dose expansion initiated in January 2025 with two specific cohorts defined (Arm 1 for platinum/PD-L1 prior therapy, Arm 2 for EGFR/PD-L1 prior therapy)
- Newer filing references December 2025 positive preliminary data from Phase 1 monotherapy study (text appears truncated)
- Removed:
- Older filing's broader description of tumor ECM as 'complex network of fibrous proteins and molecules' with discussion of embryogenesis expression of EDB+FN
- Older filing's description that MICVO can kill 'activated fibroblasts and vascular endothelial cells that support tumor growth'
- Older filing's statement that payload kills tumor cells 'through a combination of bystander effect directly killing highly proliferative cells and through stimulation of the local immune cells'
- Older filing's mention of dose response observations across nine solid tumor types with 26% ORR in six specific tumor types at therapeutic dose range
- Older filing's reference to October 2025 ESMO Congress 2025 presentation in Berlin and AACR-NCI-EORTC reference
- Reworded:
- Older: 'clinical stage oncology company executing on a development strategy designed to address' → Newer: 'clinical-stage oncology company advancing a development strategy focused on addressing'
- Older: MICVO 'formerly referred to as PYX-201' → Newer: 'formerly PYX-201'
- Older: 'Extradomain-B Fibronectin (EDB+FN)' → Newer: 'the splice variant of fibronectin, extradomain-B of fibronectin (EDB+FN)'
- Older: 'human Immunoglobulin G1 (IgG1)' → Newer: 'fully human IgG1 monoclonal antibody'
- Older: 'optimized auristatin' → Newer: 'optimized auristatin (Aur0101) microtubule inhibitor payload'
- Older: describes linker as enabling 'delivery of the next generation auristatin payload' → Newer: describes cleavable linker mechanism in detail with reference to extracellular proteases under acidic conditions
- Notes:
- Newer filing MD&A appears truncated mid-sentence at 'In December 2025, we reported positive preliminary data from our ongoing Phase 1 mon', limiting full comparison of later sections
- Older filing references 'Recent Translation Data' section beginning with October 2025 ESMO presentation, but this section is not included in the provided newer text excerpt
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 0 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 30 days · read to 2026-10-161 buy · 0 sells — 1 buying insider
- Last 90 days · read to 2026-10-161 buy · 0 sells — 1 buying insider
- Last 180 days · read to 2026-10-161 buy · 1 sell ($107100) — 1 buying, 1 selling insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-01. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PYXS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding PYXS as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 2,025,420
- Reported value $6,096,514
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about PYXS's institutional holders → See what each manager we track holds →
Short interest (FINRA)
PYXS had 4,886,652 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
PYXS had 5.86% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.05 days to cover at the same settlement.
- Reported short interest (shares) 4,886,652
- Short interest (% of shares outstanding) 5.86%
- Prior settlement (shares) 4,678,522
- Reported change 4.45%
- Days to cover (reported) 4.05
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Seagen (acquired by Pfizer)
- Immunogen (acquired by AbbVie)
- AstraZeneca (AZN)
- Gilead Sciences (GILD)
- Daiichi Sankyo (DSNKY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PYXS vs…
Pyxis Oncology, Inc. is found in…
Frequently asked questions
What does Pyxis Oncology, Inc. (PYXS) do?
Pyxis Oncology is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for patients with difficult-to-treat solid tumors. The company's lead candidate, micvotabart pelidotin (MICVO), is an antibody-drug conjugate (ADC) designed to target EDB+FN, a splice variant of fibronectin highly expressed in the tumor microenvironment.
What sector is Pyxis Oncology, Inc. (PYXS) in?
Pyxis Oncology, Inc. (PYXS) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are Pyxis Oncology, Inc.'s (PYXS) competitors?
Notable peers of Pyxis Oncology, Inc. (PYXS) include Seagen (acquired by Pfizer), Immunogen (acquired by AbbVie), AstraZeneca, Gilead Sciences and Daiichi Sankyo. This peer set is informational only — not financial advice.
Is Pyxis Oncology, Inc. (PYXS) overbought or oversold right now?
Pyxis Oncology, Inc. (PYXS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 32, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PYXS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.